CJC-1295 with DAC vs CJC-1295 without DAC: what the research compares
A comparison of the published research on CJC-1295 with Drug Affinity Complex and CJC-1295 without DAC: what each is, what studies measured, where the evidence is stronger, and what remains unknown.
CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC are both synthetic analogues of growth hormone-releasing hormone (GHRH). Both are classified in the published literature as GHRH analogues, grouped alongside sermorelin and tesamorelin, and both are described as agents encountered in the GH-IGF-1 axis category of compounds marketed as research chemicals [1]. The two forms differ in whether a drug affinity complex is attached to the peptide backbone, a modification intended to extend the compound's presence in circulation. The evidence block used for this page does not supply a sequence, molecular formula, or molecular weight for either form, so none is stated here.
The published work on both compounds centres on the GHRH receptor and the downstream growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis [1].
Research Studies
CJC-1295 with DAC and the GH-IGF-1 axis
CJC-1295 with DAC appears in the peer-reviewed literature as one of the GHRH analogues that modulate the GH-IGF-1 axis, listed together with sermorelin, tesamorelin, and CJC-1295 without DAC [1]. That review frames these agents as performance-enhancing drugs marketed as research compounds, and notes that they are unregulated peptides intended to act on the GH-IGF-1 axis [1]. The review does not report a head-to-head comparison of the DAC and non-DAC forms, and it does not report separate outcome data for the DAC form alone.
CJC-1295 without DAC and the GH-IGF-1 axis
CJC-1295 without DAC is listed in the same category of GHRH analogues acting on the GH-IGF-1 axis [1]. As with the DAC form, the review identifies the compound as an unregulated peptide marketed as a research compound and does not present separate efficacy data for it [1]. No study in the evidence block isolates the non-DAC form as its own intervention.
CJC-1295 and HIV-associated visceral obesity
The one interventional study in the evidence block that names CJC-1295 directly is a multicentre, randomized, placebo-controlled, double-blind Phase 2 trial in patients with HIV-associated visceral obesity [6]. Participants were treated for a total of 12 weeks, with a 6-week follow-up period after treatment ended, and were randomly assigned to low-dose CJC-1295, high-dose CJC-1295, or placebo [6]. The stated objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability in that population [6]. The registry record does not specify which formulation of CJC-1295 was administered, and it does not report results in the material available here.
Formulation differences and what the literature separates
The distinction between the two forms rests on the presence or absence of the Drug Affinity Complex, and the published review that names both treats them as separate entries within the same GHRH analogue class [1]. That review does not describe the pharmacokinetic consequences of the DAC modification, does not compare circulating half-life between the forms, and does not report whether one produces a different GH-IGF-1 response than the other [1]. The comparison the working title implies is therefore not one the evidence block resolves.
Purity and measured abundance in gray-market peptide preparations
A study evaluating gray-market research peptides used a large, publicly available independent testing dataset to assess purity, measured abundance, and endotoxin burden, and to compare cost against compounded and FDA-approved alternatives [2]. The dataset covered 6,441 samples [2]. The study describes peptides as a rapidly expanding drug class with a parallel, largely unregulated gray market selling preparations directly to consumers for self-administration, and notes growth in self-administration for purported benefits including musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement [2]. This work concerns gray-market peptide preparations as a category; it does not report separate purity or abundance figures for CJC-1295 with DAC versus CJC-1295 without DAC.
Peptide therapeutics and hallmarks of aging
A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions [3]. The review was conducted through systematic searches of PubMed, Scopus, and regulatory databases including the FDA and WADA, from inception through January 2026 [3]. It frames peptide therapeutics as targeting hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline [3]. The evidence block does not indicate that this review reports CJC-1295-specific findings, and no such findings are attributed to it here.
Approved and unapproved peptides in musculoskeletal and athletic contexts
Work on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describes peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and notes that use in sports medicine is expanding alongside a gray market of unapproved compounds operating largely outside regulatory oversight [4][5]. That work presents pharmacological mechanisms, safety profiles, and regulatory status for prominent approved and unapproved peptides marketed direct to patients [4][5]. CJC-1295 in either form is not identified in the evidence block as a compound for which that work reports separate outcome data.
Comparison of what the evidence block supports
| Item | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Class | GHRH analogue [1] | GHRH analogue [1] |
| Pathway named | GH-IGF-1 axis [1] | GH-IGF-1 axis [1] |
| Sequence, formula, molecular weight | Not given in evidence block | Not given in evidence block |
| Named in a registered interventional trial | Registry record names CJC-1295 without specifying formulation [6] | Registry record names CJC-1295 without specifying formulation [6] |
| Separate efficacy data in evidence block | None reported | None reported |
| Head-to-head comparison | Not present in evidence block | Not present in evidence block |
| Purity/abundance data specific to this form | Not reported separately [2] | Not reported separately [2] |
Where the evidence is stronger, and for what
The strongest single item in the evidence block that names CJC-1295 is the Phase 2 registry record in HIV-associated visceral obesity, which is randomized, placebo-controlled, double-blind, and specifies a 12-week treatment period with 6-week follow-up [6]. That record does not distinguish between the DAC and non-DAC forms, so it cannot be used to favour either one. For the class as a whole, the evidence block contains reviews and narrative syntheses [1][3][4][5] plus a large independent testing dataset on gray-market preparations [2]. None of these isolates the DAC modification as a variable.
What is simply not known from this evidence
- No sequence, molecular formula, or molecular weight for either form appears in the evidence block.
- No pharmacokinetic comparison between the DAC and non-DAC forms is reported.
- No study in the evidence block reports efficacy outcomes separately for CJC-1295 with DAC versus CJC-1295 without DAC.
- The registry record naming CJC-1295 does not state which formulation was used [6].
- Purity, measured abundance, and endotoxin findings are reported for gray-market peptides as a category, not per compound [2].
- No results from the Phase 2 trial are available in the material used here [6].
On the basis of the evidence block, the literature does not support declaring one form superior to the other. What it supports is a class-level description of both as GHRH analogues acting on the GH-IGF-1 axis [1], a single registered trial that names CJC-1295 without specifying formulation [6], and category-level findings on gray-market peptide quality [2] and on peptide therapeutics more broadly [3][4][5].
If you are reading this for personal health reasons
The compounds described on this page are sold strictly for laboratory research use. We do not provide dosing information, administration guidance, or medical advice of any kind. Anyone considering a compound for their own use should speak with a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — https://europepmc.org/article/PMC/PMC13322892
- [2] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — https://doi.org/10.20944/preprints202604.1748.v1
- [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
- [4] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity — https://clinicaltrials.gov/study/NCT00267527